K-Bio appealed for its competitiveness in Bio USA

Introduction of CDMO new growth engines and new drug development pipelines

Participated in major global partnering events in Boston, USA

Major domestic pharmaceutical bio companies participated in the '2023 Bio International Convention (Bio USA)', a global partnering event, and introduced their competitiveness.

 

Samsung Biologics disclosed an advanced target operation time for Plant 5 and a plan to build an ADC-only production plant.

 

Lotte Biologics has sought to win biopharmaceutical CMO contracts with major pharmaceutical bio companies at home and abroad.

 

Celltrion's goal to participate in the event was to increase its brand value through strengthening partnering.

 

We discovered partners and held discussions related to new drug development.

 

Bridge Biotherapeutics, Onconic Therapeutics, Inventage Lab, Abion, Vigencell, and Genome & Company announced the competitiveness of their new drug development pipelines.

 

According to the industry on the 7th, major domestic pharmaceutical bio companies participate in Bio USA and introduce their competitiveness.

 

Bio USA was held in Boston, USA on the 5th (local time).

 

It will be open until the 8th.

 

BioUSA is a global event in the biofield held every year by the American Bio Association.

 

About 15,000 biopharmaceutical companies will attend, display new technologies and biotechnology products, and hold business meetings.

 

According to the American Bio Association, 289 major domestic pharmaceutical bio companies participated in Bio USA this year.

 

Of these, 41 opened publicity booths.

 

Samsung Biologics CEO John Rim announced that BioUSA would shorten the target operating period for Plant 5 from September 2025 to April of the same year.

 

It is expected to advance construction by about a year compared to the 180,000-liter third plant of the same size.

 

According to Samsung Biologics, the early operation of Plant 5 is a strategy to preemptively respond to growing CDMO demand.

 

In addition, the fact that new contracts with customers and the volume of existing agreements are increasing also influenced the decision to operate early.

 

Starting with the 5th factory's construction, the 2nd Bio Campus will begin in earnest.

 

Additional production facilities and an open innovation center will be built on the 2nd Bio Campus.

 

The total investment is 7.5 trillion won.

 

CEO John Rim also announced that he would build a production facility exclusively for ADC biopharmaceuticals to participate in the ADC market, which has recently attracted attention.

 

Considering the market growth potential, it plans to start production of ADC commercial products within 2024.

 

Lotte Biologics promoted the Syracuse plant's manufacturing technology, process development service, and quality system.

 

It also revealed plans to build a large-scale factory in Korea by 2030 by spending 3 trillion won.

 

Lotte Biologics prepared a meeting table and a private meeting room inside the booth.

 

We discuss partnering for biopharmaceutical CMOs with about 30 major domestic and foreign pharmaceutical companies and bio companies that have been coordinated in advance.

 

Celltrion participated in Bio USA and set up a promotional booth.

 

(Photo by Celltrion)

Celltrion and other bio companies engaged in the development of new drugs have also started to discover partners and introduce pipelines.

 

Celltrion promoted its technological competitiveness and brand to leap forward as a new drug development company.

 

An open meeting space and a private meeting room were set up inside the booth to discuss business.

 

Potential partners were also explored to discover new modalities and new drug candidates.

 

In the future, discussions for joint development are also planned.

 

An official from Bridge Biotherapeutics introduces their new drug pipeline.

 

(Photo by Bridge Bio)

Bridge Biotherapeutics presented its corporate competitiveness and pipeline to industry officials.

 

Business Development Director Pavel Princeev introduced major clinical challenges in the field of lung cancer and fibrosis, which the company is strategically focusing on.

 

The fourth-generation lung cancer drug candidate 'BBT-176' phase 1 clinical trial data and self-discovered BBT-207 were shared.

 

Innovative diagnosis technology recently acquired was also disclosed.

 

Onconic Therapeutics sought additional technology transfer for its major pipeline P-CAB-type gastroesophageal reflux disease drug candidate 'Zastaprazan'.

 

In addition, it introduced follow-up pipelines such as 'OCN-201', a dual inhibitor target anti-cancer drug.

 

We plan to discuss building partnerships with domestic and foreign pharmaceutical bio companies.

 

Inventage Lab introduced pipelines 'IVL3001' and 'IVL3002' using the long-acting injectable platform technology 'IVL-Drug Fluidics'.

 

Data on the Alzheimer's treatment candidate 'IVL3003', drug/alcohol addiction candidate 'IVL3004', and prostate cancer treatment candidates 'IVL3008' and 'IVL3016' were also announced.

 

It also presented a blueprint to enter the lipid nanoparticle (LNP) CDMO business based on the gene therapy development platform technology 'IVL-Genefluidic'.

 

Abion promoted the technology transfer of 'ABN401', a c-MET treatment for non-small cell lung cancer, which is undergoing global phase 2 clinical trials, and 'ABN501', a candidate material in the non-clinical stage.

 

Participating in K-Bio Showcase, a side event of Bio USA, introduces the representative pipeline to global investors and industry officials.

 

Genome & Company will unveil its microbiome immuno-oncology treatment pipeline.

 

Through more than 20 meetings, it has started strengthening business partnerships with domestic and foreign pharmaceutical companies.

 

We introduce the development status of GEN-001', a major pipeline, and new target immuno-anticancer drug candidates GENA-104 and GENA-111.

 

In addition to technology transfer, meetings related to joint development will be held.